SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of bluebird bio, Inc. Common Stock and Sets a Lead Plaintiff Deadline of May 28, 2024

/EIN News/ -- NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive. You are hereby notified that the class action lawsuit Garry Gill v. bluebird bio, Inc., et al. (Case No. 1:24-cv-10803) has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:

https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher.

Following this news, Blue’s stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.

If you suffered a loss in BLUE common stock, you have until May 28, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP  
Joseph E. Levi, Esq. 
Ed Korsinsky, Esq. 
33 Whitehall Street, 17th Floor 
New York, NY 10004 
jlevi@levikorsinsky.com 
Tel: (212) 363-7500 
Fax: (212) 363-7171 
www.zlk.com